-
Forum
-
Supplementarium
-
Healing
-
Osteoarthritis
-
BMP-7
-
Ember Therapeutics phase 2 knee trial
Ember Therapeutics phase 2 knee trial
Less
More
-
Posts: 213
-
Karma: 4
-
Thank you received: 0
-
-
-
-
Less
More
-
Posts: 213
-
Karma: 4
-
Thank you received: 0
-
-
-
-
8 years 9 months ago #4925
by admin
I have reservations about BMP-7, even if the Ember Therapeutics study sounds good superficially.
Here's from the Yano study from Ann Rheum Dis 2013;72:
A novel disease-modifying osteoarthritis drug candidate targeting Runx1
The major action of TD-198946 is distinct from the actions of the above strategies: it strongly induces chondrogenic differentiation of progenitors, as evidenced by a marked increase in the chondrogenic markers type II collagen and aggrecan, and it does this without promoting hypertrophy, which is often and undesirably observed with conventional chondrogenic agents including BMPs,21 TGF-β,13 insulin21 and insulin-like growth factor-1.22
Ember hasn't published anything yet it seems nor mentioned anything about adverse events, so I'm very curious if they came across any of this.
Please Log in to join the conversation.
Less
More
-
Posts: 10
-
Karma: 2
-
Thank you received: 0
-
-
8 years 9 months ago #4927
by repellent
Yes I feel BMP-7 is a powerful drug and just grows anything. There was a company advert which highlighted how excess cartilage from BMP7 had to be removed from the joint (in animal study), but thats the power if it growing tissue. I suppose the trouble in an OA joint is in some parts we have bone where we want cartilage and it may cause excessive bone growth in these areas. Perhaps with surgical intervention, i.e microfracture it may come into it's own, but again just an opinion
Please Log in to join the conversation.
-
Forum
-
Supplementarium
-
Healing
-
Osteoarthritis
-
BMP-7
-
Ember Therapeutics phase 2 knee trial
Time to create page: 0.067 seconds